Tema Etfs LLC Makes New $513,000 Investment in BioNTech SE (NASDAQ:BNTX)

Tema Etfs LLC acquired a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,500 shares of the company's stock, valued at approximately $513,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of BioNTech in the 4th quarter worth $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after acquiring an additional 433,388 shares during the period. Capital International Investors boosted its position in shares of BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares during the last quarter. Finally, abrdn plc grew its holdings in shares of BioNTech by 70.7% in the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after purchasing an additional 159,676 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 2.6%

Shares of NASDAQ:BNTX traded down $2.63 on Wednesday, hitting $99.09. 768,332 shares of the company's stock were exchanged, compared to its average volume of 938,430. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a market capitalization of $23.82 billion, a PE ratio of -47.19 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm's 50-day moving average is $97.45 and its 200 day moving average is $108.67.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the prior year, the company posted $1.90 earnings per share. The firm's quarterly revenue was down 19.5% compared to the same quarter last year. Sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BNTX. HC Wainwright reiterated a "buy" rating and issued a $134.00 price objective (down from $145.00) on shares of BioNTech in a report on Wednesday, May 14th. Citigroup reissued a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Morgan Stanley decreased their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $142.08.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.